Search

Displaying results 4581 - 4590 of 10000 in total
  1. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured … In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.

  2. Drug

    Pivekimab sunirine

    go.drugbank.com/drugs/DB17337
    ApprovedInvestigational

  3. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  4. Drug

    Chlormidazole

    go.drugbank.com/drugs/DB13611
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  5. Drug

    Sulfathiourea

    go.drugbank.com/drugs/DB13699
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] It is administered by direct injection into superficial, deep, or visceral tumors. … Vusolimogene oderparepvec-wtpg is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy used, in combination with [nivolumab], to treat advanced melanoma.

  7. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

  8. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  9. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    It is prepared from the Connaught strain of Bacillus Calmette and Guérin. … Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary

  10. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.